Published in Mol Cancer on November 19, 2014
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med (2000) 6.20
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol (2008) 5.90
ROS stress in cancer cells and therapeutic implications. Drug Resist Updat (2004) 5.20
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68
The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell (2011) 4.43
CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol (2001) 4.13
The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75
Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68
A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (1995) 3.58
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
CD69 is an immunoregulatory molecule induced following activation. Trends Immunol (2005) 2.83
Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 2.72
ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell (2009) 2.46
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst (1999) 2.41
"The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci (2004) 2.29
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem (2003) 2.19
Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol (2006) 2.14
A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer (1995) 2.12
Heat-shock proteins as regulators of apoptosis. Oncogene (2003) 1.97
Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood (1999) 1.83
Arsenical-based cancer drugs. Cancer Treat Rev (2007) 1.78
Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol (2012) 1.50
Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A (2004) 1.49
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood (2003) 1.38
Heat shock proteins in cancer. Ann N Y Acad Sci (2007) 1.38
CD45: all is not yet crystal clear. Immunology (2006) 1.30
Curing APL through PML/RARA degradation by As2O3. Trends Mol Med (2011) 1.27
Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med (1996) 1.25
Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A (2010) 1.21
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood (2006) 1.19
Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood (2000) 1.18
Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood (1999) 1.18
Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol (2003) 1.13
Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer (1999) 1.08
Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol (1998) 1.03
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther (2003) 1.02
Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood (2006) 0.97
T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci (2012) 0.96
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood (2007) 0.92
Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene (2005) 0.92
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol (2009) 0.90
CD45 ligation induces programmed cell death in T and B lymphocytes. J Immunol (1996) 0.89
Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Mol Oncol (2011) 0.85
Human T cell activation induces the expression of a novel CD45 isoform that is analogous to murine B220 and is associated with altered O-glycan synthesis and onset of apoptosis. Cell Immunol (2001) 0.84
Effects of hemizygous CD45 expression in the autoimmune Fasl(gld/gld) syndrome. Cell Immunol (2001) 0.78
Loss of P2X7 receptor plasma membrane expression and function in pathogenic B220+ double-negative T lymphocytes of autoimmune MRL/lpr mice. PLoS One (2012) 0.78